ストックスクリーナーアプリを入手
3.74
0.80%
-0.03
アフターアワーズ：
3.74
前日終値:
$3.77
開ける：
$3.76
24時間の取引高:
69,691
Relative Volume:
0.26
時価総額：
$178.05M
収益：
$114.70K
当期純損益:
$-37.06M
株価収益率:
-0.9367
EPS:
-3.9929
ネットキャッシュフロー:
$-30.69M
1週間 パフォーマンス:
-2.60%
1か月 パフォーマンス:
-5.32%
6か月 パフォーマンス:
+113.11%
1年 パフォーマンス:
-1.43%
1日の値動き範囲:
$3.68
$3.80
1週間の範囲:
$3.4802
$3.87
52週間の値動き範囲:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
SABS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.74 | 179.48M | 114.70K | -37.06M | -30.69M | -3.9929 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-19 | 開始されました | Guggenheim | Buy |
| 2025-09-17 | 開始されました | Leerink Partners | Outperform |
| 2025-05-14 | 再開されました | H.C. Wainwright | Buy |
| 2024-10-09 | 開始されました | Craig Hallum | Buy |
| 2024-08-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Sab Biotherapeutics Inc (SABS) 最新ニュース
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Increase in Short Interest - MarketBeat
SAB Biotherapeutics Files $300 Million Mixed Shelf - marketscreener.com
Sab Biotherapeutics files for offering of up to $300 mln - marketscreener.com
SAB Biotherapeutics enters sales agreement with UBS SecuritiesSEC filing - marketscreener.com
SAB Biotherapeutics Launches New $75 Million ATM Program - TipRanks
SAB Biotherapeutics Establishes New At-the-Market Offering Program - TradingView — Track All Markets
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is SAB Biotherapeutics Inc. stock a good choice for value investorsBlue Chip Stock Analysis & Free Professional Investment Consultations - bollywoodhelpline.com
SABS SEC FilingsSAB BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
SAB Biotherapeutics Earnings Notes - Trefis
Will SAB Biotherapeutics Inc. Equity Warrant stock continue dividend increases2025 Pullback Review & AI Forecasted Entry and Exit Points - Улправда
What margin trends mean for SAB Biotherapeutics Inc. stockJuly 2025 Setups & Verified Entry Point Detection - Улправда
Guggenheim Initiates Coverage of SAB Biotherapeutics (SABS) with Buy Recommendation - Nasdaq
Will SAB Biotherapeutics Inc. stock continue dividend increases2025 Macro Impact & Weekly Chart Analysis and Trade Guides - DonanımHaber
Guggenheim Initiates Coverage on SAB Biotherapeutics With Buy Rating, $15 Price Target - marketscreener.com
Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential - Investing.com Canada
Will SAB Biotherapeutics Inc. Equity Warrant stock deliver consistent dividends2025 Risk Factors & Real-Time Chart Breakout Alerts - DonanımHaber
Will SAB Biotherapeutics Inc. Equity Warrant stock outperform international peers2025 Technical Overview & Community Verified Watchlist Alerts - Улправда
Why SAB Biotherapeutics Inc. stock is favored by top institutionsProfit Target & Low Risk High Reward Trade Ideas - Улправда
SAB Biotherapeutics’ (SABS) Buy Rating Reaffirmed at Chardan Capital - Defense World
Will SAB Biotherapeutics Inc. Equity Warrant stock continue upward momentum2025 Support & Resistance & Low Volatility Stock Suggestions - Улправда
SAB Biotherapeutics (SABS) director Jay S. Skyler granted 150,000 stock options - Stock Titan
Chardan Capital Maintains SAB Biotherapeutics (SABS) Buy Recommendation - Nasdaq
SAB Biotherapeutics (SABS) director awarded 150,000 stock options for 2025 - Stock Titan
SAB Biotherapeutics grants director option for 150,000 shares at $3.99 | SABS SEC FilingForm 4 - Stock Titan
SAB Biotherapeutics (SABS) director gets 150,000 options at $3.99 - Stock Titan
SAB Biotherapeutics grants director options for 150,000 shares | SABS SEC FilingForm 4 - Stock Titan
SAB Biotherapeutics (SABS) director awarded 150,000 stock options - Stock Titan
Aug EndMonth: Is SAB Biotherapeutics Inc. stock a good choice for value investorsRisk Management & Long Hold Capital Preservation Plans - Улправда
Will SAB Biotherapeutics Inc. stock benefit from green energy trendsTrade Risk Assessment & Stepwise Swing Trade Plans - Улправда
SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial - TipRanks
SAB Biotherapeutics' (SABS) Buy Rating Reiterated at Chardan Capital - MarketBeat
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D - The Manila Times
SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint - TipRanks
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D - Investing News Network
SAB Biotherapeutics Confirms Positive Phase 1 Results for SAB-142, Advancing to Phase 2b Trial for Type 1 Diabetes Treatment - Quiver Quantitative
SAB Bio announces positive confirmatory clinical results - marketscreener.com
Early trial of new type 1 diabetes drug shows no serum sickness - Stock Titan
SABS Options Overview History for Sab Biotherapeutics Stock - Barchart.com
SAB Biotherapeutics (SABS) adds 24,180,000 shares to 2021 equity plan - Stock Titan
SAB Biotherapeutics, Inc. (SABS) CMO details RSU-related share withholding - Stock Titan
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management - Investing News Network
SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at ATTD-Asia Conference 2025 - Quiver Quantitative
SAB Biotherapeutics (SABS) Stock Analysis Report | Financials & Insights - Benzinga
Institution Moves: Is Above Food Ingredients Inc. stock safe for conservative investorsNew Guidance & Technical Pattern Based Buy Signals - BỘ NỘI VỤ
Why analysts upgrade SAB Biotherapeutics Inc. Equity Warrant stockQuarterly Portfolio Review & Safe Swing Trade Setups - Newser
Will SAB Biotherapeutics Inc. Equity Warrant stock gain from lower inflationMarket Movers & Consistent Growth Equity Picks - Newser
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
How SAB Biotherapeutics Inc. stock performs in rate cut cyclesWeekly Profit Report & AI Forecast Swing Trade Picks - Newser
Will SAB Biotherapeutics Inc. Equity Warrant stock reach Wall Street targetsTrade Analysis Report & Daily Volume Surge Signals - Newser
Sab Biotherapeutics Inc (SABS) 財務データ
収益
当期純利益
現金流量
EPS
Sab Biotherapeutics Inc (SABS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
0.90%
大文字化:
|
ボリューム (24 時間):